ArticlePaediatrics & child health2026
Incidence and clinical management of paediatric emergency presentations of anaphylaxis in Alberta.
Article in Paediatrics & child health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Anaphylaxis represents a growing burden on emergency services worldwide; however, long-term paediatric trends are poorly understood. This study examined the incidence, clinical features, management, and outcomes of paediatric emergency department (ED) presentations for anaphylaxis in a western Canadian province and forecasted future visit rates. Methods: This population-based retrospective cohort study used linked administrative health data for all paediatric (<18 years) ED presentations for anaphylaxis in Alberta, between 2004 and 2024. Temporal trends were assessed with time-series models and logistic regression identified factors for hospitalization. Results: Over the study period, 11,012 anaphylaxis visits were identified (median age 8 years [IQR, 3 to 14]; 57.9% male). Food was the most common trigger (71.1%), although nearly 1 in 4 had no clear cause. The incidence of anaphylaxis ED visits quadrupled, from ∼25 per 100,000 in 2004/05 to 113 per 100,000 in 2023/24, with forecasts projecting a continued rise. Epinephrine was administered in 41.9% of ED encounters and 19.5% of ambulance transports. Hospitalization was infrequent (3.7%); however, it was significantly associated with higher triage acuity (aOR = 1.45; 95% CI: 1.10 to 1.90), higher comorbidity scores (aOR = 1.31; 95% CI: 1.17 to 1.48), and drug-related triggers (aOR = 2.45; 95% CI: 1.60 to 3.75). Females had a significantly higher and earlier risk of 30-day ED revisit for anaphylaxis ( Conclusion: Paediatric presentations to Alberta EDs for anaphylaxis have quadrupled and are forecasted to continue increasing. First-line epinephrine is severely underutilized, especially prehospital. Further studies are needed to identify factors underlying the observed sex differences and upward trajectories and bridge potential system and policy gaps in "Epi-Care."
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.